897 related articles for article (PubMed ID: 22267471)
1. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.
Chen J; Wang Z; Zhou B; Wang Y; Hou J
Antivir Ther; 2012; 17(1):71-9. PubMed ID: 22267471
[TBL] [Abstract][Full Text] [Related]
2. [Changes of serum HBsAg in HBeAg positive chronic hepatitis patients with sustained viral response to long-term lamivudine treatment].
Chen JJ; Wang ZH; Ma SW; Chen YP; Peng J; Guo YB; Hou JL
Zhonghua Gan Zang Bing Za Zhi; 2008 Jun; 16(6):416-20. PubMed ID: 18578990
[TBL] [Abstract][Full Text] [Related]
3. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
4. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S
J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
[TBL] [Abstract][Full Text] [Related]
5. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
6. Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy.
Su CW; Wu CY; Hung HH; Wu CH; Sheen IJ; Wu JC
J Gastroenterol Hepatol; 2013 Dec; 28(12):1849-58. PubMed ID: 23730852
[TBL] [Abstract][Full Text] [Related]
7. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
8. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
[TBL] [Abstract][Full Text] [Related]
10. Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients.
Gramenzi A; Loggi E; Micco L; Cursaro C; Fiorino S; Galli S; Gitto S; Galli C; Furlini G; Bernardi M; Andreone P
J Viral Hepat; 2011 Oct; 18(10):e468-74. PubMed ID: 21914065
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir.
Reijnders JG; Rijckborst V; Sonneveld MJ; Scherbeijn SM; Boucher CA; Hansen BE; Janssen HL
J Hepatol; 2011 Mar; 54(3):449-54. PubMed ID: 21112655
[TBL] [Abstract][Full Text] [Related]
12. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.
Chan HL; Wong GL; Chim AM; Chan HY; Chu SH; Wong VW
Antivir Ther; 2011; 16(8):1249-57. PubMed ID: 22155906
[TBL] [Abstract][Full Text] [Related]
13. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.
Wong GL; Chan HL; Lo AO; Chan HY; Tse CH; Chim AM; Wong VW
Antivir Ther; 2013; 18(8):979-86. PubMed ID: 23744529
[TBL] [Abstract][Full Text] [Related]
14. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
[TBL] [Abstract][Full Text] [Related]
15. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.
Tseng TC; Liu CJ; Su TH; Wang CC; Chen CL; Chen PJ; Chen DS; Kao JH
Gastroenterology; 2011 Aug; 141(2):517-25, 525.e1-2. PubMed ID: 21672542
[TBL] [Abstract][Full Text] [Related]
16. Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.
Wiegand J; Brosteanu O; Kullig U; Wiese M; Berr F; Maier M; Tillmann HL; Schiefke I
Z Gastroenterol; 2011 Nov; 49(11):1463-9. PubMed ID: 22069045
[TBL] [Abstract][Full Text] [Related]
17. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
18. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.
Shin JW; Jung SW; Park BR; Kim CJ; Eum JB; Kim BG; Jeong ID; Bang SJ; Lee SH; Kim SR; Park NH
J Viral Hepat; 2012 Oct; 19(10):724-31. PubMed ID: 22967104
[TBL] [Abstract][Full Text] [Related]
19. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.
Cai W; Xie Q; An B; Wang H; Zhou X; Zhao G; Guo Q; Gu R; Bao S
J Clin Virol; 2010 May; 48(1):22-6. PubMed ID: 20233672
[TBL] [Abstract][Full Text] [Related]
20. Telbivudine versus lamivudine in patients with chronic hepatitis B.
Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
